Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin

Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.